{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:41:56Z","timestamp":1772412116090,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.semarthrit.2020.03.015","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T14:08:39Z","timestamp":1589551719000},"page":"709-718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study"],"prefix":"10.1016","volume":"50","author":[{"given":"Laura C.","family":"Coates","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Nash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tore K.","family":"Kvien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Rasouliyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luminita","family":"Pricop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen M.","family":"Jugl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunal K.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corine","family":"Gaillez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef S.","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2020.03.015_bib0001","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0002","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.det.2014.09.010","article-title":"Psoriatic arthritis for the dermatologist","volume":"33","author":"Tintle","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0003","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","article-title":"Enthesitis: from pathophysiology to treatment","volume":"13","author":"Schett","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0004","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","article-title":"International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials","volume":"76","author":"Orbai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nrrheum.2017.96","article-title":"Why location matters - site-specific factors in rheumatic diseases","volume":"13","author":"Ospelt","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0006","first-page":"68","article-title":"Clinical assessment in psoriatic arthritis","volume":"59","author":"Salvarani","year":"2007","journal-title":"Reumatismo"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0007","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11926-017-0642-z","article-title":"The changing face of clinical trials in psoriatic arthritis","volume":"19","author":"Ogdie","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0008","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0009","first-page":"S48","article-title":"Disease activity and response assessment in psoriatic arthritis using the disease activity index for psoriatic arthritis (DAPSA). A brief review","volume":"33","author":"Smolen","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0011","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European league against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0012","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.semarthrit.2017.10.021","article-title":"Considerations for the definition of remission criteria in psoriatic arthritis","volume":"47","author":"Mease","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0013","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nrrheum.2016.183","article-title":"Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPArecommendations","volume":"12","author":"Gossec","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0014","article-title":"To DAPSA or not to DAPSA? That is not the question","author":"Schoels","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0015","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/annrheumdis-2016-209511","article-title":"Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression","volume":"76","author":"Aletaha","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0016","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/annrheumdis-2015-208617","article-title":"Treating to target in psoriatic arthritis: how to implement in clinical practice","volume":"75","author":"Coates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0017","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0018","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/acr.20155","article-title":"Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data","volume":"62","author":"Coates","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0019","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/BOR.0000000000000387","article-title":"Minimal disease activity in axial spondyloarthritis: the need of the hour and a proposal for development","volume":"29","author":"Deodhar","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0020","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/acr.23537","article-title":"Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2-year results from a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase III study","volume":"70","author":"Coates","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0021","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0022","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0023","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","article-title":"Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study","volume":"56","author":"McInnes","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0024","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3899\/jrheum.180267","article-title":"What should be the primary target of \"Treat to Target\" in psoriatic arthritis?","volume":"46","author":"Coates","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0025","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13075-018-1773-y","article-title":"Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study","volume":"20","author":"Coates","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0026","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/rheumatology\/key359","article-title":"Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab","volume":"58","author":"Coates","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0027","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3899\/jrheum.180249","article-title":"Comparison of different remission and low disease definitions in psoriatic arthritis and evaluation of their prognostic value","volume":"46","author":"Coates","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0028","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3899\/jrheum.170112","article-title":"Comparison of composite indices tailored for psoriatic arthritis treated with csDMARD and bDMARD: a cross-sectional analysis of a longitudinal cohort","volume":"44","author":"Lubrano","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0029","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/annrheumdis-2017-211998","article-title":"Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort","volume":"77","author":"Van Mens","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0030","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/acr.23571","article-title":"Burden of psoriatic arthritis according to different definitions of disease activity: comparing minimal disease activity and the disease activity index for psoriatic arthritis","volume":"70","author":"Wervers","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0031","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/annrheumdis-2017-eular.3762","article-title":"Outcomes associated with achievement of various treatment targets in patients with psoriatic arthritis receiving adalimumab","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0032","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0033","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/annrheumdis-2018-214140","article-title":"Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries","volume":"78","author":"Gorlier","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0034","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/rheumatology\/key004","article-title":"Early response to therapy predicts 6-month and 1-year disease activity outcomes in psoriatic arthritis patients","volume":"57","author":"Schoels","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000582","article-title":"4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis","volume":"4","author":"van der Heijde","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0036","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3899\/jrheum.120970","article-title":"Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT","volume":"40","author":"Mease","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0037","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/acr.22576","article-title":"Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo-controlled study","volume":"68","author":"Kavanaugh","year":"2016","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0038","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2016-eular.1397","article-title":"Ixekizumab provides sustained improvement up to 52 weeks of disease activity as assessed by composite measure scores in biologic disease-modifying antirheumatic drug (bDMARD)-naive patients with active psoriatic arthritis","volume":"75","author":"Coates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.03.015_bib0039","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722030086X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722030086X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:03:35Z","timestamp":1758733415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004901722030086X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S004901722030086X"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.03.015","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}